Tricol Biomedical, Inc.
Tricol Biomedical, Inc. (formerly HemCon Medical Technologies, Inc.) is a global leader in hemostasis and infection control products with a full range of devices under the HemCon brand indicated for professional medical, surgical, trauma, military, and consumer OTC (over the counter) applications.
Tricol Biomedical, Inc. is a wholly owned independent subsidiary of Tricol International Group, Ltd., a Marshall Islands company, substantially owned by Weifang Tricol Trading Co. Ltd. the largest manufacturer in Asia for microfiber products, with capabilities of manufacturing chitosan microfibers and non-woven sheets and films.
Tricol is a strong supplier of microfiber technologies brands worldwide for healthcare and cleaning products. Tricol acquired HemCon Medical Technologies, Inc. in April 2016.
Tricol Biomedical is headquartered in Portland, Oregon with a wholly owned operating subsidiary in Ireland (HemCon Medical Technologies Europe Ltd.) and the Czech Republic (HemCon Medical Technologies CZ s.r.o.).
Tricol Biomedical, Inc. is ISO 13485 certified.